A systematic review highlights that early-stage alcohol use disorder (AUD) medication trials often overlook sex differences and relapse prevention, suggesting a need for more inclusive study designs to identify therapeutic effects in women and high-risk populations.
A preliminary study suggests that obesity exacerbates metabolic alterations in alcohol use disorder, potentially intensifying cravings and supporting the investigation of GLP-1 agonists as a treatment for AUD.
A clinical trial demonstrates that targeting the dorsolateral prefrontal cortex with rTMS significantly reduces cigarette consumption and cravings in smokers, offering a non-pharmacologic alternative for patients who cannot tolerate or fail standard cessation therapies.
A double-blind sham-controlled trial evaluates the efficacy of intermittent theta burst stimulation (iTBS) as a neuromodulation intervention for negative symptoms in schizophrenia, addressing a key limitation of current pharmacotherapy.
This randomized controlled trial compares the clinical efficacy, safety, and EEG functional connectivity changes of two accelerated deep TMS protocols (18-Hz rTMS vs. iTBS) for major depressive disorder.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Aug 26 – May 11)
- Prescribe lumateperone for treatment-resistant depression but counsel patients proactively about the high likelihood of discontinuation due to side effects.
- Utilize IV ketamine as a rapid-acting intervention for acute suicidal ideation when immediate risk reduction is required.
- Monitor height and weight Z-scores in children and adolescents on methylphenidate to manage the small but significant risk of growth suppression.
- Consider rTMS targeting the dorsolateral prefrontal cortex as a non-pharmacologic alternative for smoking cessation in patients who fail or cannot tolerate standard therapies.
- Evaluate the risk of treatment-emergent mania carefully when initiating antidepressants in pediatric populations, acknowledging the ongoing debate regarding this adverse effect.
- Use vortioxetine for major depressive disorder when a multimodal serotonergic mechanism is desired, keeping its specific efficacy and tolerability profile in mind.
- Recognize that high-dose psilocybin shows low abuse potential in preclinical models, supporting its safety profile for therapeutic use despite its psychedelic nature.
- Select antidopaminergic versus muscarinic antipsychotics for acute schizophrenia based on the latest network meta-analysis data regarding comparative efficacy and tolerability.
- Consider the potential of GLP-1 agonists for alcohol use disorder, particularly in patients with obesity where metabolic alterations may exacerbate cravings.
- Account for CYP3A4 genetic variability when prescribing citalopram, as specific variants can significantly alter antidepressant clearance rates.
Drug Development 1
This article reviews the modification of natural tryptamines for neuropsychiatric diseases, reflecting ongoing research into psychedelic pharmacotherapy.
Substance Use 1
Emerging data suggests psilocybin may offer therapeutic benefits for patients with cocaine use disorder, indicating potential for novel pharmacotherapies in substance use treatment.
Journal Article 5
A meta-analysis confirms that methylphenidate is associated with small but significant reductions in height and weight Z-scores in children and adolescents with ADHD, supporting the need for individualized growth monitoring during treatment.
Meta-analyses in JAMA Psychiatry confirm IV ketamine's rapid efficacy for suicidal ideation and highlight lumateperone's symptom reduction despite high discontinuation rates due to side effects in treatment-resistant depression.
This network meta-analysis compares the efficacy and tolerability of antidopaminergic versus muscarinic antipsychotics for acute schizophrenia, providing evidence-based guidance for prescribing decisions in this population.
A real-world cohort study investigates the risk of treatment-emergent mania in children and adolescents initiating antidepressants, addressing ongoing debate regarding this adverse effect in pediatric populations.
This meta-analysis evaluates the pharmacological modulation of panic responses using the 35% CO2 inhalation model, providing evidence for the efficacy of various drug classes in treating panic disorder.
Policy & Regulation 1
The FDA has approved the first non-antipsychotic medication for treating agitation in patients with Alzheimer's disease, marking a significant shift in the pharmacological management of dementia-related behavioral symptoms.
Mechanism of Action 5
Research indicates that a single dose of psilocybin may provide weeks of relief by reshaping brain connectivity, highlighting a potential mechanism for its therapeutic effects in psychiatric conditions.
The D2 antagonist (-)-OSU6162 reduces context-conditioned fear freezing in rats, suggesting potential utility in treating anxiety disorders characterized by pathological fear responses.
An in vitro study characterizes how 21 CYP3A4 variants differentially metabolize citalopram, providing mechanistic data relevant to pharmacogenomic variability in antidepressant clearance.
High-dose psilocybin in rats produces acute behavioral changes but does not induce conditioned place preference, suggesting a low potential for abuse despite its therapeutic interest.
Preclinical data show that TAAR1 activation reduces mania-relevant behaviors in a bipolar disorder mouse model, highlighting a potential novel therapeutic target for risky decision-making in BD.
Clinical Pearl 1
A randomized crossover trial investigates the effects of a herbal supplement (Scutellaria baicalensis/Crataegus laevigata) combined with magnesium and chromium on stressed individuals, providing clinical data on a non-prescription intervention for stress management.